(Q42282507)

English

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

scientific article published on 20 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Linda Chang

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Peter N Morcos

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Rohit Kulkarni

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Mylene Giraudon

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Nancy Shulman

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Barbara J Brennan

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Patrick F Smith

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jonathan Q Tran

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1939-1949

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

https://scigraph.springernature.com/pub.10.1007/s00228-013-1556-y

0 references

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Review and management of drug interactions with boceprevir and telaprevir

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Induction effects of ritonavir: implications for drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Clinical-pharmacological strategies to assess drug interaction potential during drug development

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1556-Y

21 January 2018

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23872824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23872824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/23872824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-013-1556-Y

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42282507&oldid=1941007561"